Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
Status:
Completed
Trial end date:
2020-09-17
Target enrollment:
Participant gender:
Summary
Study Objectives
1. Evaluate the efficacy of the combination of thalidomide (Thalomid®), clarithromycin
(Biaxin®), lenalidomide (Revlimid®), and dexamethasone (Decadron®) as an induction
therapy for patients with newly diagnosed multiple myeloma (MM).
2. Evaluate the efficacy of the addition of thalidomide (Thalomid®) to BiRD combination
therapy as a therapy to increase the complete response rate for patients with newly
diagnosed multiple myeloma.
3. Evaluate the safety of the combination of clarithromycin, lenalidomide, dexamethasone,
and thalidomide as a therapy for patients with newly diagnosed MM